Veterinary Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type (Canine, Feline, Others), By Treatment Type (Radiotherapy, Surgery, Chemotherapy, Others), By Cancer Type (Skin Cancers, Lymphomas, Sarcomas, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.82 Billion
CAGR (2026-2031)	12.14%
Fastest Growing Segment	Radiotherapy
Largest Market	North America
Market Size (2031)	USD 3.62 Billion

Market Overview

The Global Veterinary Oncology Market will grow from USD 1.82 Billion in 2025 to USD 3.62 Billion by 2031 at a 12.14% CAGR. The Global Veterinary Oncology Market encompasses the comprehensive range of diagnostic modalities, surgical interventions, and therapeutic agents—including chemotherapy and immunotherapy—utilized to manage cancer in companion animals. This market is primarily propelled by the rising prevalence of neoplastic diseases in aging pet populations and the deepening human-animal bond, which motivates owners to seek specialized veterinary care. Furthermore, the robust expansion of the pet insurance sector is acting as a critical economic enabler; according to the North American Pet Health Insurance Association, in 2024, the total premium volume for the sector in North America reached $5.2 billion. This financial growth allows more pet owners to afford complex oncological procedures that were previously inaccessible due to cost.

Despite this positive trajectory, the market faces a significant impediment in the form of prohibitive treatment expenses, which often deter owners from pursuing long-term care plans. This economic barrier is frequently compounded by a global shortage of board-certified veterinary oncologists, limiting the availability of specialized services in many regions and potentially stifling broader market expansion.

Key Market Drivers

Rising prevalence of cancer in companion animals is the primary catalyst driving the Global Veterinary Oncology Market. As pets live longer due to improved general care, the incidence of neoplastic diseases has surged, necessitating more frequent and sophisticated oncological interventions. This trend is quantitatively supported by recent epidemiological data; according to a study published in PLOS One, April 2024, the overall tumor incidence rate in dogs was calculated at 775 per 100,000 dog-years at risk, with skin tumors representing the largest category at 34.64% of diagnosed cases. This growing patient volume is met by a substantial increase in owner spending power and willingness to invest in medical outcomes. According to the American Pet Products Association, in March 2024, annual U.S. veterinary care and product sales reached $38.3 billion, illustrating the robust financial ecosystem that enables the adoption of these critical oncology services.

Development of novel targeted therapies and immunotherapies is simultaneously transforming the clinical landscape, moving the market beyond traditional chemotherapy toward precision medicine. Pharmaceutical companies and biotech firms are increasingly leveraging artificial intelligence and genomic profiling to create tailored treatment regimens that offer higher efficacy and fewer side effects. A prime example of this technological shift is evident in recent clinical outcomes for lymphoma management. According to ImpriMed, March 2024, dogs with high-grade T-cell lymphoma that received a high proportion of AI-predicted treatments achieved a remission rate of 59%, significantly outperforming the 9.1% remission rate observed in the low-matching group. These advancements not only improve survival rates but also validate the commercial viability of sophisticated oncological solutions, encouraging further R&D investment in the sector.

Download Free Sample Report

Key Market Challenges

Prohibitive treatment expenses represent a formidable challenge hampering the expansion of the Global Veterinary Oncology Market. The escalating costs associated with advanced cancer care, including diagnostics, specialized surgery, and long-term chemotherapy, often surpass the financial capacity of many pet owners. This economic disparity frequently forces clients to decline recommended oncological interventions, opting instead for less expensive palliative measures or euthanasia. Such financial limitations directly suppress the volume of complex procedures performed, thereby stifling the revenue growth of specialized veterinary centers and pharmaceutical suppliers who rely on the widespread adoption of these therapies.

This financial sensitivity is reflected in recent industry data indicating a contraction in consumer expenditure on animal healthcare, which disproportionately affects high-cost specialties. According to the American Veterinary Medical Association, in 2024, overall veterinary spending decreased by 4% compared to the prior year as pet owners faced tightening budgets. This reduction in spending capacity limits the addressable market for expensive oncology treatments, as financial feasibility remains a primary decision-making factor for clients. Consequently, the market faces capped growth potential as the high price point of effective cancer management renders it inaccessible to a significant portion of the pet-owning population.

Key Market Trends

Emergence of Liquid Biopsy and Non-Invasive Diagnostic Testing is revolutionizing the detection of neoplastic diseases by shifting focus from invasive tissue sampling to blood-based biomarker screening. This diagnostic modality allows veterinarians to identify circulating tumor DNA or nucleosomes at earlier stages of disease progression, significantly improving prognostic accuracy and monitoring capabilities without the risks associated with surgical biopsies. The commercial adoption of these accessible screening tools is accelerating rapidly as they become integrated into routine wellness checks for aging pets. According to VolitionRx, December 2024, the company sold approximately 50,000 units of its Nu.Q Vet Cancer Screening Test in the third quarter alone, underscoring the high market demand for reliable, non-invasive diagnostic solutions.

Advancements in Stereotactic and Mobile Radiation Therapy Technologies are simultaneously reshaping treatment protocols by enabling the delivery of high-dose radiation with sub-millimeter precision. Unlike traditional fractionated radiotherapy that requires numerous anesthetic events over several weeks, stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) typically condense treatment into one to three sessions, thereby reducing patient stress and anesthesia-related risks. This technological evolution is expanding the treatable patient base to include cases previously considered unresectable or too medically fragile for conventional courses. According to Thrive Pet Healthcare, April 2024, its specialty partner PetCure Oncology reached a significant clinical milestone by administering these advanced radiation therapies to over 8,000 pets, validating the growing reliance on precise, high-efficiency therapeutic modalities.

Segmental Insights

The Radiotherapy segment is recognized as the fastest-growing category within the Global Veterinary Oncology Market. This rapid expansion is primarily driven by the integration of advanced technologies, such as stereotactic radiation therapy and linear accelerators, which deliver precise radiation doses while minimizing damage to surrounding healthy tissues. These innovations have significantly reduced treatment sessions and side effects, aligning with the rising demand from pet owners for non-invasive, quality-of-life-focused care. Furthermore, the standardization of safety guidelines by institutions like the International Atomic Energy Agency has facilitated broader clinical adoption, reinforcing the segment's robust development globally.

Regional Insights

North America maintains a dominant position in the global veterinary oncology market, driven by rising pet ownership and increased spending on animal healthcare. The region benefits from substantial veterinary infrastructure and the strong presence of key pharmaceutical manufacturers focusing on cancer therapies. Additionally, favorable initiatives by regulatory bodies, such as the U.S. Food and Drug Administration, facilitate the approval process for new animal drugs. This regulatory support, combined with a growing emphasis on early disease diagnosis and treatment, ensures the continued expansion of the veterinary oncology sector across the United States and Canada.

Recent Developments

• In March 2025, VolitionRx Limited announced the expansion of its supply agreement with Fujifilm Vet Systems Co. Ltd. to include a new automated version of its veterinary cancer screening test. The collaboration aimed to introduce the chemiluminescent immunoassay (ChLIA) format of the Nu.Q Vet Cancer Test on the Immunodiagnostic Systems (IDS) i10 analyzer platform. This agreement extended the partnership for a new five-year initial term and targeted a commercial launch in Japan by the summer of 2025. The initiative was designed to facilitate higher throughput and rapid turnaround times for canine cancer screening in the Japanese market.
• In August 2024, Akston Biosciences Corporation entered into a strategic partnership with Purdue University to co-develop a novel immunotherapy for canine cancer. The collaboration focused on advancing an anti-cPD-L1 monoclonal antibody that utilized the university’s underlying research technology. Under the agreement, the company received an exclusive option to license the therapy and assumed the role of a contract development and manufacturing organization. The partners planned to initiate clinical trials to evaluate the safety and antitumor effects of the treatment in dogs with bladder cancer, aiming to bring a new biologic solution to the veterinary market.
• In May 2024, ImpriMed introduced its AI-driven Drug Response Predictions service to the veterinary oncology market. This innovative precision medicine tool was developed to forecast how individual canine patients with lymphoma or leukemia would respond to specific anticancer treatments. By analyzing live cancer cells alongside the patient's medical history, the service provided veterinarians with personalized insights to optimize therapeutic strategies. The launch was intended to reduce trial-and-error in prescribing, enhance treatment efficacy, and improve the quality of life for dogs suffering from blood cancers, addressing a growing demand for individualized care.
• In April 2024, Antech Diagnostics expanded its oncology portfolio by launching the Nu.Q Canine Cancer Test in the European market. This breakthrough diagnostic tool was designed to assist veterinarians in screening for prevalent cancer types in high-risk breeds and older dogs during routine wellness visits. The test, which operated on the company’s Element i+ Immunodiagnostic Analyzer, measured circulating nucleosomes to support early disease detection. By providing accurate results within minutes at the point of care, this launch aimed to enable informed decision-making and improve clinical outcomes for companion animals across Europe.

Key Market Players

• Elanco Animal Health Incorporated
• Boehringer Ingelheim International GmbH
• Zoetis Inc.
• Elekta AB
• PetCure Oncology
• Accuray Incorporated
• Varian Medical Systems, Inc.
• Virbac S.A.
• Merck & Co., Inc.
• Dechra Pharmaceuticals PLC
• NovaVive Inc.
• Ardent Animal Health, LLC

By Animal Type	By Treatment Type	By Cancer Type	By Region
Canine Feline Others	Radiotherapy Surgery Chemotherapy Others	Skin Cancers Lymphomas Sarcomas Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Veterinary Oncology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Oncology Market, By Animal Type:

• Canine
• Feline
• Others

• Veterinary Oncology Market, By Treatment Type:

• Radiotherapy
• Surgery
• Chemotherapy
• Others

• Veterinary Oncology Market, By Cancer Type:

• Skin Cancers
• Lymphomas
• Sarcomas
• Others

• Veterinary Oncology Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE